Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism
- 1 December 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (12) , 3707-3718
- https://doi.org/10.1158/1535-7163.mct-08-0507
Abstract
The microsomal antiestrogen-binding site (AEBS) is a high-affinity membranous binding site for the antitumor drug tamoxifen that selectively binds diphenylmethane derivatives of tamoxifen such as PBPE and mediates their antiproliferative properties. The AEBS is a hetero-oligomeric complex consisting of 3 beta-hydroxysterol-Delta(8)-Delta(7)-isomerase and 3 beta-hydroxysterol-Delta(7)-reductase. High-affinity AEBS ligands inhibit these enzymes leading to the massive intracellular accumulation of zymostenol or 7-dehydrocholesterol (DHC), thus linking AEBS binding to the modulation of cholesterol metabolism and growth control. The aim of the present study was to gain more insight into the control of breast cancer cell growth by AEBS ligands. We report that PBPE and tamoxifen treatment induced differentiation in human breast adenocarcinoma cells MCF-7 as indicated by the arrest of cells in the G(0)-G(1) chase of the cell cycle, the increase in the cell volume, the accumulation and secretion of lipids, and a milk fat globule protein found in milk. These effects were observed with other AEBS ligands and with zymostenol and DHC. Vitamin E abrogates the induction of differentiation and reverses the control of cell growth produced by AEBS ligands, zymostenol, and DHC, showing the importance of the oxidative processes in this effect. AEBS ligands induced differentiation in estrogen receptor-negative mammary tumor cell lines SKBr-3 and MDA-MB-468 but with a lower efficiency than observed with MCF-7. Together, these data show that AEBS ligands exert an anti-proliferative effect on mammary cancer cells by inducing cell differentiation and growth arrest and highlight the importance of cholesterol metabolism in these effects. [Mol Cancer Ther 2008;7(12):3707-18]Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pumpMedical Hypotheses, 2006
- Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactationCell Metabolism, 2006
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move ForwardClinical Cancer Research, 2006
- OSBP Is a Cholesterol-Regulated Scaffolding Protein in Control of ERK1/2 ActivationScience, 2005
- Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactationJournal of Lipid Research, 2003
- The lipids in human milkProgress in Lipid Research, 1996
- Differentiation induction in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2ABiochemical and Biophysical Research Communications, 1992
- A diphenylmethane derivative selective for the anti-estrogen binding site may help define its biological roleBiochemical and Biophysical Research Communications, 1984
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959